Results 211 to 220 of about 17,772 (222)

Inflammatory Cortical Demyelination in Early Multiple Sclerosis

New England Journal of Medicine, 2011
Hans Lassmann, Wolfgang Brück, Joseph E Parisi   +2 more
exaly  

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

New England Journal of Medicine, 2008
Stephen L Hauser, Emmanuelle Waubant, Douglas L Arnold   +2 more
exaly  

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Nature Reviews Drug Discovery, 2010
exaly  

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

New England Journal of Medicine, 2017
Stephen L Hauser, Amit Bar-or, Giancarlo Comi   +2 more
exaly  

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

New England Journal of Medicine, 2017
Xavier Montalban, Stephen L Hauser, Ludwig Kappos   +2 more
exaly  

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

New England Journal of Medicine, 2012
Robert J Fox, Michael Hutchinson, Vissia Viglietta   +2 more
exaly  

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

New England Journal of Medicine, 2012
Ludwig Kappos, Douglas L Arnold, Gavin Giovannoni   +2 more
exaly  

Mesial temporal sclerosis.

Neurology India, 1999
M B, Rao, K, Radhakrishnan
openaire   +1 more source

FDA reversal sends mixed message to multiple sclerosis community

Nature Reviews Drug Discovery, 2014
exaly  

The multiple sclerosis market

Nature Reviews Drug Discovery, 2017
exaly